CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. In particular, we are focused on evaluating pacritinib for the treatment of adult patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington. Source
No articles found.
Acer is a pharmaceutical company focused on the acquisition, development and comme...
Acer is a pharmaceutical company focused on the...
IMAC Holdings, Inc. owns or manages IMAC Regeneration Centers, which combine life ...
IMAC Holdings, Inc. owns or manages IMAC Regene...
BrainsWay is an industry leader in the field of transcranial magnetic stimulation ...
BrainsWay is an industry leader in the field of...
Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving pa...
Alexion (NASDAQ: ALXN) is a global biopharmaceu...
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy ...
Atara Biotherapeutics is a leading off-the-shel...
ProPhase Labs is a diversified medical science and technology company. We develop,...
ProPhase Labs is a diversified medical science ...
Seattle-based Atossa Genetics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical...
Seattle-based Atossa Genetics (NASDAQ: ATOS) is...
Join the National Investor Network and get the latest information with your interests in mind.